Double-Punch cancer therapy trial seeks to tame aggressive myeloma
NCT ID NCT07093554
Summary
This study is testing whether using a drug called talquetamab before a personalized cell therapy (cilta-cel) is safe and feasible for people with multiple myeloma that has returned or stopped responding to treatment. The research will enroll 31 adults who have already tried at least one standard treatment. The goal is to see if this combination approach can better control the cancer while managing side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Froedtert & the Medical College of Wisconsin
RECRUITINGMilwaukee, Wisconsin, 53226, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.